A Phase 1, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of CC-90011 in Subjects With Advanced Solid Tumors and Non-Hodgkin Lymphomas
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs CC 90011 (Primary)
- Indications Diffuse large B cell lymphoma; Neuroendocrine carcinoma; Non-Hodgkin's lymphoma; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 27 Sep 2017 Planned End Date changed from 24 Mar 2021 to 18 Jun 2021.
- 08 Dec 2016 Planned number of patients changed from 70 to 115.
- 08 Dec 2016 Status changed from not yet recruiting to recruiting.